Abstract:Background: Chronic activation of the innate immune system drives inflammation and contributes directly to atherosclerosis. Previously, we showed that macrophages in the atherogenic plaque undergo RIPK3-MLKL-dependent programmed necroptosis in response to sterile ligands such as oxidized LDL and damage-associated patterns (DAMPs) and necroptosis is active in advanced atherosclerotic plaques. Upstream of the RIPK3-MLKL necroptotic machinery lies RIPK1, which acts as a master switch that controls whether the cell undergoes NFκB-dependent inflammation, caspase-dependent apoptosis or necroptosis in response to extracellular stimuli. We therefore set out to investigate the role of RIPK1 in the development of atherosclerosis, which is largely driven by NFκB-dependent inflammation at early stages. We hypothesize that, unlike RIPK3 and MLKL, RIPK1 primarily drives NFκB-dependent inflammation in early atherogenic lesions and knocking down RIPK1 will reduce inflammatory cell activation and protect against the progression of atherosclerosis. Methods: We examined expression of RIPK1 protein and mRNA in both human and mouse atherosclerotic lesions, and using loss-of-function approaches in vitro in macrophages and endothelial cells to measure inflammatory responses. We administered weekly injections of RIPK1 anti-sense oligonucleotides (ASO) to Apoe -/- mice fed a cholesterol-rich (Western) diet for 8 weeks. Results: We find RIPK1 expression is abundant in early-stage atherosclerotic lesions in both humans and mice. Treatment with RIPK1 ASOs led to a reduction in aortic sinus and en face lesion areas (47.2% or 58.8% decrease relative to control, p<0.01) and plasma inflammatory cytokines (IL-1α, IL-17A, p<0.05) compared to controls. RIPK1 knockdown in macrophages decreased inflammatory genes (NFκB, TNFα, IL-1α) and in vivo LPS- and atherogenic diet-induced NF-κB activation. In endothelial cells, knockdown of RIPK1 prevented NF-κB translocation to the nucleus in response to TNFα, where accordingly there was a reduction in gene expression of IL1B, E-selectin and monocyte attachment. Conclusions: We have identified RIPK1 as a central driver of inflammation in atherosclerosis by its ability to activate the NF-κB pathway and promote inflammatory cytokine release. Given the high levels of RIPK1 expression in human atherosclerotic lesions, our study suggests RIPK1 as a future therapeutic target to reduce residual inflammation in patients at high risk of coronary artery disease.

NF-κB inhibition in keratinocytes causes RIPK1-mediated necroptosis and skin inflammation

ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis

The interplay of IKK, NF-κB and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation

[Research Progress on Receptor Interacting Proteins in Inflammation].

RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis

Sensing of endogenous nucleic acids by ZBP1 induces keratinocyte necroptosis and skin inflammation

OTULIN inhibits RIPK1-mediated keratinocyte necroptosis to prevent skin inflammation in mice

TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members

RIP1 kinase activity is critical for skin inflammation but not for viral propagation

Regulation of Innate Immune Responses by Receptor Interacting Protein Kinases (172.43)

Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO.

RNF31 Regulates Skin Homeostasis by Protecting Epidermal Keratinocytes from Cell Death.

A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1

RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation

Necroptosis-independent signaling by the RIP kinases in inflammation

RIPK1 Expression Associates with Inflammation in Early Atherosclerosis in Humans and Can be Therapeutically Silenced to Reduce NF-κB Activation and Atherogenesis in Mice

The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation

Type I Immune Response Induces Keratinocyte Necroptosis and is Associated with Interface Dermatitis.

RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis

The Necroptosis Adaptor RIPK3 Promotes Injury-Induced Cytokine Expression and Tissue Repair

Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo.